Ciara Metcalfe

Gene Therapy Laboratory — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index2.8kcitations204works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(73), Advanced Breast Cancer Therapies(72), HER2/EGFR in Cancer Research(36), Cancer Genomics and Diagnostics(21), Hedgehog Signaling Pathway Studies(18)

Publications204 total

Abstract PS1-12-11: Giredestrant immobilizes the Estrogen Receptor to potently suppress ER-active breast cancers
Clinical Cancer Research·2026
Supplementary Fig. 1 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. 3 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. 6 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. 2 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. 5 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
2025Open Access
Supplementary Fig. 4 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
2025Open Access
Supplementary Data 1 from An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
2025Open Access
Epiregulon: Single-cell transcription factor activity inference to predict drug response and drivers of cell states
Nature Communications·2025Open Access
Supplementary Table 6 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
2025Open Access
Supplementary Table 3 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
2025Open Access
Data from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
2025Open Access
Supplementary Figure 4 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
2025Open Access
Supplementary Table 1 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
2025Open Access
Supplementary Table 5 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
2025Open Access
Supplementary Table 8 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
2025Open Access
Supplementary Figure 2 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
2025Open Access
Supplementary Figure 1 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
2025Open Access
Supplementary Table 2 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
2025Open Access
Supplementary Figure 3 from Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer
2025Open Access
page 1 of 11Next →

Frequent Co-authors

Marc Hafner(15), Ellen Ingalla(13), Lori S. Friedman(13), Robert A. Blake(11), Jennifer M. Giltnane(11), Deepak Sampath(10), Jane Guan(9), Michelle Nannini(9), Amy Young(9), Steven J. Hartman(8), Tracy Kleinheinz(8), Anneleen Daemen(8), Mary Gates(8), Heather M. Moore(8), Frédéric J. de Sauvage(7), Ingrid E. Wertz(7), Jeffrey H. Hager(6), Vidhi Mody(6), Jennifer Lauchle(6), Aditya Bardia(6)